Based in San Diego, Axiom Biosciences is set to seek a primary listing in Hong Kong in 2027, followed by...
-
-
Recent Updates
- Hong Kong’s Asset Management Sector Set to Boom Following Tax Reforms: KPMG Report
- Europe’s Citric Acid Industry Faces Existential Threat from Chinese Competition
- Intelligent Energy Expands Hydrogen UAV Technology in China’s Growing Low-Altitude Sector
- US Plans to Limit Foreign Drones Import, Nixes China-Made Models
- American Biotech Firm Axiom Biosciences to List in Hong Kong Before Wall Street
- Nike’s Bold Move: Restructuring Online Presence in China
- Huawei’s Advancements in Own Memory Production Presents Unexpected Challenge to Tech Giants
- China teens tell parents they’re on holiday, secretly join flood relief effort: ‘It’s not about being a hero’
- China Southern Power Grid Showcases AI Innovations at World AI Conference
- EU lawmakers arrive in China for high-stakes talks to manage mounting tensions
Blogroll